JNJ
JOHNSON & JOHNSON
Healthcare • CIK: 0000200406
Loading...
Market Cap
$578.94B
P/E (TTM)
27.5x
Rev Growth (TTM)
+7.9%
Net Margin (TTM)
21.8%
FCF Yield (TTM)
3.1%
FCF Margin (TTM)
18.5%
Cash Flow Health
Free Cash Flow8/8 positive
TTM$17.8B
Q1 '26
$1.5B-73%
Q4 '25
$5.5B-32%
FCF Margin
TTM18.5%
Q1 '266.1%-73%
Sector: 0.0%Top 10%
OCF Margin23.7%
OCF/NI1.09x
CapEx Coverage4.5x
FCF Yield3.1%
FCF Growth (2Y)+3%
Cash Conversion Cycle
108 days
DSO: 66+DIO: 163−DPO: 121
Capital Allocation & Returns
Balanced
Total Shareholder YieldTTM
TTM3.5%
Div Yield2.2%
+Buyback (TTM)1.4%
Balancing returns with reinvestment
Dividend & Payout Metrics
Dividend Yield (TTM)2.2%
FCF Payout Ratio70.4%
Free Cash Flow (TTM)$17.8B
Stock Repurchases (TTM)$7.9B
Capital Return / FCF114.6%
Est. Dividends Paid (TTM)$12.5B
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
16.8%
Stable
+0.0% YoY+0.7%
P25MedianP75
75th pctl (med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
22.6%
8Q: 23.0%
Asset Turnover
0.49x
8Q: 0.50x
Leverage (1+D/E)
1.68x
D/E: 0.68x
DuPont: 18.7% ≈ 16.8% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
4.31x
8Q:4.36x
-30.3%
Invested Cap Turn
0.79x
8Q:0.80x
-8.4%
CapEx Intensity
4.2%
8Q:3.8%
CapEx/Depreciation
0.66x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $96.4B | $24.1B↓2.0% | $24.6B↑2.4% | $24.0B↑1.1% | $23.7B↑8.5% | $21.9B↓2.8% | $22.5B↑0.2% | $22.5B↑0.1% | $22.4B |
Operating Income | $25.8B | $6.4B↑14.4% | $5.6B↓21.2% | $7.1B↑5.8% | $6.7B↑8.2% | $6.2B↑70.3% | $3.6B↓28.3% | $5.1B↓21.4% | $6.5B |
Net Income | $21.0B | $5.2B↑2.3% | $5.1B↓0.7% | $5.2B↓7.0% | $5.5B↓49.7% | $11.0B↑220.6% | $3.4B↑27.4% | $2.7B↓42.5% | $4.7B |
Operating Cash Flow | $22.9B | $2.5B↓65.6% | $7.3B↓20.3% | $9.2B↑136.4% | $3.9B↓7.1% | $4.2B↓40.2% | $7.0B↓12.6% | $8.0B↑41.9% | $5.6B |
Free Cash Flow | $17.8B | $1.5B↓73.2% | $5.5B↓31.7% | $8.0B↑182.6% | $2.8B↓16.1% | $3.4B↓37.1% | $5.4B↓22.9% | $7.0B↑49.5% | $4.7B |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
27.5x
Volatile
8Q: 91.0x-33%
High PEG ratio (3.5x) suggests expensive for growth
Valuation Lenses
Earnings
27.5x
vs – sector
Cash Flow
34.1x
EV/FCF vs –
Growth-Adj
3.5xPEG
Expensive for growth
Quality-Adj
1.6P/E per %ROIC
ROIC: 16.8%
Shareholder Returns
Dividend
2.2%
Buyback
1.4%
Total Yield
3.5%
Market Cap$578.94B
EV$606.48B
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
97/100
Exceptional
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Top 25%
26.4%
8Q:–
Return on Invested Capital (ROIC)Top 25%
16.8%
8Q:–
Flat
vs Sector:-0.0%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 22.6%
Asset Turnover: 0.49x
Earnings Quality
Cash Conversion
1.09x
OCF / Net Income ✓
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin67.8%
Capital Efficiency
Invested Capital Turnover0.79x
Working Capital
Cash Conversion Cycle108 days
Growth Quality & Momentum
Moderate Growth
Growth Quality Score
59/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
7.9%
OpInc Growth YoY
3.2%
EPS Growth YoY
-3.9%
FCF 3Y CAGR
3.1%
Margin Quality & Sustainability
Moderate
Profitability Cascade
Gross
67.8%
Operating
26.8%
Top 25% in sector
Net
21.8%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
-3.4 pts
FCF: 18.5% | Net: 21.8%
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Adequate
Net Debt / EBITDA
–Net Debt: $32.94B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.68x
Balance sheet risk & solvency analysis